Sign up
Pharma Capital

Cellmid expanding products, portfolio and markets; and approaching profitablity

Cellmid Limited (ASX:CDY) CEO Maria Halasz speaks to Proactive Investors about the company's diversified and global operations, and recent cash raise.

"We are fully funded are really ready to make this company a profitable entity. So the majority of the funding we really raised for our consumer health business. We have so many opportunities now in all the the different geographical regions, and we really want to put product through, make sure that we can support that growth," says Halasz.

In addition to notable advancements in the consumer health business, Cellmid has been progressing its global portfolio of intellectual property relating to midkine (MK) research, convening the 5th Midkine Symposium in Munich, Germany in May.

Halasz explains, "Midkine is a protein that we all have... It really only appears in the body in adults as part of the pathogenesis of certain diseases, and therefore it is an important disease target. We at Cellmid hold literally all the intellectual property globally around this new target for disease management and treatment, and so this is a very exciting area."


View full CDY profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.